Drug intelligence / Profile preview

Ganqing granules

Development stage: Unknown
Lead developer: Tianjin University of Traditional Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Ganqing granules is an investigational Traditional Chinese Medicine (TCM) herbal formulation developed by the Tianjin University of Traditional Chinese Medicine. It is primarily studied for the treatment of non-alcoholic fatty liver disease (NAFLD), specifically for patients diagnosed with the 'phlegm-blood stasis syndrome' (痰瘀阻络证) according to TCM principles. The formulation aims to reduce hepatic fat accumulation and improve liver function, with clinical efficacy measured by liver/spleen CT ratio and ultrasound imaging.

Other names: Ganqing Keli

Beyond the preview

Go deeper on Ganqing granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganqing granules.

Explore the full profile